Tacoma WA 癌症(所有类型)临床试验
6项针对 癌症(所有类型)的研究正在 Tacoma及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
招募中3 期
- Vista Oncology Inc PS, Olympia · 距离 26 英里
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- Northwest Medical Specialties, Tacoma
- Northwest Medical Specialties, Gig Harbor · 距离 8 英里
- Northwest Medical Specialties, Puyallup · 距离 8 英里
- 以及另外 1 项
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
招募中1/2 期
- Northwest Medical Specialties Tacoma /ID# 272506, Tacoma
Project: Every Child for Younger Patients With Cancer
招募中观察性研究
- Mary Bridge Children's Hospital and Health Center, Tacoma
- Madigan Army Medical Center, Tacoma
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
招募中3 期
- Providence Regional Cancer System-Lacey, Lacey · 距离 23 英里
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- Northwest Medical Specialties Tacoma /ID# 267117, Tacoma
其他城市的 癌症(所有类型)试验
- Houston, TX121 项研究
- New York City, NY109 项研究
- Boston, MA85 项研究
- Los Angeles, CA74 项研究
- Nashville, TN65 项研究
- Philadelphia, PA59 项研究
- Washington, DC58 项研究
- Durham, NC58 项研究
- Chicago, IL51 项研究
- Atlanta, GA49 项研究
- Seattle, WA49 项研究
- Arlington, VA48 项研究
Tacoma的其他研究
- 非小细胞肺癌20 项研究
- 乳腺癌18 项研究
- 溃疡性结肠炎15 项研究
- 多发性骨髓瘤13 项研究
- 前列腺癌11 项研究
- 克罗恩病11 项研究
- 结直肠癌9 项研究
- 转移性癌症9 项研究
- 黑色素瘤7 项研究
- 卵巢癌7 项研究
- 胃癌6 项研究
- 食管癌6 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。